Abstract. Limited treatment results in advanced pediatric liver tumors have emphasized the need for alternative treatment approaches in these malignancies. Photodynamic therapy (PDT) has been proposed as a promising treatment approach in various malignancies. Hypericin, a naturally occurring substance found in the St. John’s Wort, has regularly and successfully been used for visualization and as photosensitizer in various tumor models. However, there exist no data on the effects of hypericin as a photodynamic agent in pediatric malignant epithelial liver tumors. In this study, we investigated the potential role of hypericin for visualization and treatment in hepatoblastoma (HB) and pediatric hepatocellular carcinoma (HCC) cells. Two HB cell lines (HUH6, HepT1) and one HCC cell line (HepG2) were incubated with ascending concentrations of hypericin. Uptake and fluorescencing capability were assessed using fluorescence microscopy and FACS. PDT with white light was performed for varying time intervals. Cell viability, cell proliferation and apoptotic rates were assessed using MTT assay, Ki-67 immunocytochemistry and TUNEL test, respectively. The changes within tumor cells under therapy were monitored using standard cytology. Relevant hypericin uptake was observed in all cell lines according to the applied concentrations. Histological analysis revealed no alterations of cell structure in HB and HCC cells after solely hypericin uptake, but severe alterations were found after PDT. Enhancement of the hypericin concentration (up to 12.5 μM) and illumination time of up to 40 min resulted in a decrease of tumor cell viability (HUH6 99.8±2.4%, HepT1 99±2%, HepG2 98.4±1.6%, p<0.05), proliferative activity and complete apoptosis of all cells in all investigated cell lines. These data show that hypericin might be a useful tool for visualization and as an alternative treatment option in HB and HCC.

Introduction

Human hepatoblastoma (HB) is the most common primary malignant liver tumor in infants and children. During the past decades improvements of treatment results were achieved in standard tumors. Standard risk HB-patients have a 3-year overall survival of 91% and within this group, disease-free survival in stage I and II patients is 98-100%. However, advanced HB, relapsed or metastasized tumors still are associated with a poor prognosis. The 3-year overall survival rate for patients with high-risk HB is 53% and the disease-free survival in stage IV is ~36% (1,2). Hepatocellular carcinoma (HCC) is a rare tumor entity in children. The outcome of these patients is worse compared to hepatoblastoma (3). The 5-year overall survival is 28% and the event-free survival >75 months is only 17% (4). In order to improve those data, additional approaches have become necessary especially since no essential progress has been achieved by established treatment options.

Photodynamic therapy (PDT) is a novel anticancer approach based on administration of a non- or weakly-toxic photosensitizer. PDT depends on the delivery of a photosensitizer to the target tissue. Light exposure with light of the appropriate wavelength causes production of singlet oxygen (5), which causes apoptotic cell death (6).

Hypericin is a hydroxylated phenanthroperylenequinone derivate and is found in plants of the St. John’s Wort (7). The most common species is Hypericum perforatum (8). Hypericin is currently under evaluation for different tumor types such as rhabdomyosarcoma (7), nasopharyngeal carcinoma (9) or colon carcinoma (5). Besides its photodynamic abilities, it can be also used for the detection of tumor cells in vivo (10). To now, there is no data on PDT in liver malignancies.

The aim of this study was to evaluate the effects of hypericin-induced photodynamic therapy as a novel promising treatment option for advanced stage hepatoblastoma and hepatocellular carcinoma in vitro. Furthermore, we wanted to figure out if in vitro visualization of tumor cells might be
feasible and could improve the identification of safety margins in liver surgery.

Materials and methods

Cell lines and culture conditions. The cell line HUH6 originates from a mixed HB. The tumor presents chondro-osteogenic tissue and extra medullar haematopoiesis. Tumor cells have a caryotype with 48 chromosomes (11). The cell line HepT1 was derived from an embryonal HB. The caryotype is polyploid with 65-125 chromosomes per cell, deletions on 1p and 11q and a 6q15 translocation (12). The cell line HepG2 was derived from a pediatric hepatocellular carcinoma of trabecular type. The caryotype consists of 50-56 chromosomes per cell with several isoforms of chromosome 1. The hepatitis B surface antigen (HbsAg) is also expressed (13).

All tumor cells were grown as monolayer in Dulbecco's MEM medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum, 1% glutamine and 2.5% HEPES buffer (Gibco, Eggenstein, Germany). The cells were grown at 37˚C in a humidified atmosphere containing 5% carbon dioxide. All cells were mycoplasma species negative.

Hypericin experiments. HUH6, HepT2 and HepG2 cells (5x10³) were seeded out in 8-well chamber slides (Falcon Becton-Dickinson Labware, Franklin Lakes, NJ, USA, #354108, 200 μl/well) and were cultured as described before (1). After 24 h, the medium was removed and hypericin (Phytochem, Neu-Ulm, Germany) dissolved in DMSO was added in increasing concentrations (0, 2.5, 5, 7.5, 10 and 12.5 μM). Cells were incubated for 2 h in a humified atmosphere containing 10% CO₂ at 37°C without exposure to light. After an incubation time of 2 h, the hypericin solution was replaced by standard medium. Fluorescence microscopy [Zeiss AxioVision, Jena, Germany, filter set 15, #480015-0000, excitation 546 nm (+12/-12 nm), emission 570-650 nm] was taken to evaluate hypericin uptake in cancer cells.

For photodynamic therapy, cells were treated as described above and additionally exposed to white light (1000 Lux, Osram, Germany) under a clean bench (Heraeus, HLB 2472 GS, Germany) for 0, 10, 20, 30, 40 or 50 min. Cells were cultured in the dark up to day 5. MTT assay, Ki-67 assay and TUNEL test were performed at day 5, as described below.

Cell morphology. Cancer cells were examined for possible changes in cell morphology after hypericin treatment by a pathologist. Therefore, light microscopy was used. Tumor cells without application of hypericin (controls), after hypericin treatment (0, 2.5, 5, 7.5, 10 and 12.5 μM) without exposure to light, and after hypericin treatment (0, 2.5, 5, 7.5, 10 and 12.5 μM) with exposure to light for 0, 10, and 50 min were investigated.

FACS analysis. Cells were incubated with above-mentioned hypericin concentrations for 2 h until trypsinisation. All experiments were performed in the dark. Hypericin uptake was analysed using a FACS CANTO flow cytometer (BD Heidelberg, Germany) and Flow Jo Software (Tree Star Inc., Stanford, USA). Fluorescence intensity of hypericin was detected using a blue-green laser with excitation at 488 nm and emission at 575 nm. The percentage of labelled cells and mean fluorescence intensity of labelled cells were calculated using unlabelled cells as background. The hypericin uptake was estimated by the mean fluorescence index (MFI), which was the ratio between the mean fluorescence of the positive cell population and of the negative control.

Cell viability. Cell viability was assessed using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]-assay (Biomedica EZ4U, Biozol, Germany) at day 5. Therefore, substrate was dissolved in activator solution and 20 μl was added to each well. Incubation time was 5 h. Afterwards, absorption was measured by an ELISA reader (Tecan Spectra Mini, Grödig, Austria) at 450 nm against a reference at 620 nm.

Cell proliferation. In order to investigate cell proliferation, a Ki-67 immunocytochemistry assay was carried out at day 5. A hypericin concentration of 5 μM was used due to complete destruction of tumor cells at higher concentrations. Cells were rinsed in PBS and then fixed with Roti-Histofix (Roth, #2213.3, Karlsruhe, Germany) for 10 min. After fixation, cells were rinsed in PBS for 5 min. Blocking was performed using 1.5% normal goat serum (Dako, #X0907, Glostrup, Denmark) for 30 min followed by monoclonal mouse anti-human Ki-67–primary antibody-clone MIB-1 (Dako Cytoformation, #M7240, Glostrup, Denmark, dilution 1:100) for 60 min at room temperature. Slides were rinsed for 3x5 min in PBS. A FITC-conjugated secondary goat anti-mouse antibody (Dianova, #115-095-062, Hamburg, Germany, dilution 1:100) was added for 30 min at room temperature, followed by a PBS washing step (3x5 min). For counterstaining of the nucleus, DAPI was used for 1 min (Sigma-Aldrich, #D-9452, Germany, dilution 1:10000) followed by another PBS washing step. Slides were mounted (Dako mounting medium, Glostrup, Denmark) and analyzed using fluorescence microscopy (Zeiss AxioVision). Therefore, 300 cells per slide were counted in triplicate.

TUNEL test. Detection of possible apoptosis in cancer cells was revealed by a Terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling test (TUNEL). This test was performed at day 5. Different concentrations of hypericin (0, 2.5, 5, 10 and 12.5 μM) and irradiation times of 0, 10 and 50 min were used for these experiments. Chambers were removed and slides were rinsed in PBS. Cells were then fixed with Roth-Histofix (Roth, Munich, Germany) and again rinsed in PBS (3 times). Slides were incubated in 0.1% Triton/PBS (Merck, Darmstadt, Germany) on ice for 2 min and rinsed with PBS again. TUNEL reaction solution (50 μl/well, Roche Diagnostics, #1684795, Pinzberg, Germany) was added for 60 min at 37°C. For positive controls, cells were incubated with DNase I (1:10 in PBS, 15 min at room temperature, Roche Diagnostics). The TUNEL reaction solution was added, as described above. For negative controls, 50 μl/well of labelling solution (Roche Diagnostics, #1684795) was added. Slides were rinsed in PBS (x3). For nuclear counterstaining,
DAPI was used for 1 min (Sigma-Aldrich, dilution 1:10000) followed by 3x5 min PBS. Slides were mounted, as described above and analyzed by fluorescence microscopy. Therefore, 300 cells per slide were counted in triplicate.

Statistical analysis. Statistical analysis on cell vitality (MTT assay), Ki-67 immunocytochemistry and TUNEL-test was performed between the groups using one way ANOVA on ranks test. Data were tested against a control group (hypericin 0 μM, 0 min illumination time) using a Dunn's test. All numeric data are expressed as mean ± SEM. Significance was assumed for all p<0.05. FACS data were analyzed by linear regression and slope confidence intervals of MFI vs. concentration curves using GraphPad Prism software (Version 4.00 for windows, GraphPad Software, San Diego, CA, USA).

Results

Biodistribution. A hypericin uptake was found in all tumor cell lines leading to a strong fluorescence signal. Quantitative assessment of cellular hypericin fluorescence using FACS analysis showed increasing uptake of hypericin with increasing concentrations in HUH6, HepT1 and HepG2 cell lines. The highest fluorescence signal was found in HUH6 cells (MFI 697.83) and lowest fluorescence signal in HepT1 (MFI 437.14) (Fig. 1).

Cell morphology. Possible changes in cell morphology after photodynamic therapy were analysed by light microscopy. Cell lines after application of hypericin without exposure to light and negative controls exhibited large sheets and clusters of tumor cells with epithelial features. The tumor cells showed a high nuclear cytoplasmic ratio with large nuclei containing prominent nucleoli. After photodynamic treatment the density of cells and cell cohesion were reduced and the clusters of cells were smaller. The effect was dependent on the concentration of hypericin and the duration of photodynamic treatment. When treatment was carried out for 30 min and at high hypericin concentrations (12.5 μM), there were usually few clusters of cohesive cells left and scattered cells with pyknotic nuclei were found.

Cell viability. Illumination with white light without application of hypericin had no effect on tumor cell viability in any of the cell lines. Application of increasing concentrations of hypericin without illumination showed an increase in tumor cell viability in all tumor cell lines. The highest tumor cell viability was found at the highest hypericin concentration (50 μM) in both hepatoblastoma cell lines (HepT: 121±9.5%, HUH6 131±15%). In the hepatocellular carcinoma cell line HepG2, the highest cell viability was found at a concentration of 5 μM hypericin (145±5%). Enhancement of the hypericin concentration and illumination time resulted in a decrease of tumor cell viability in all cell lines. In the hepatocellular carcinoma cell line HepG2, a minimum hypericin concentration of 10 μM hypericin and an illumination time of 20 min or more were required to kill nearly all tumor cells (98.4±1.6%, p<0.05, Fig. 2). In the hepatoblastoma cell line HepT1, a hypericin concentration of 12.5 μM hypericin and exposure to light for 30 min was required to destroy 99% of the cells (±2, p<0.05, Fig. 3). In the hepatoblastoma cell line HUH6, a hypericin concentration of 12.5 μM hypericin and an illumination time of 40 min were necessary to kill 99.8% of the cells (±2.4, p<0.05, Fig. 4).

Cell proliferation. Ki-67 immunocytochemistry revealed a reduction of proliferating cells with increasing concentrations of hypericin and exposure to light. After incubation with 5 μM hypericin and exposure to light for 20 min, a significant reduction of the proliferative activity was detected in all cancer cells (HepT1: 70%, HUH6: 46%, HepG2: 46%, p<0.05 compared vs. control 0 μM, 0 min). At illumination times of 50 min in HUH6 cells, the number of Ki-67-positive cells was also lower, but some proliferating cells could still be detected (3.7±0.89 cells, p<0.05 vs. control). In HepT1 and HepG2 cell lines only few proliferating cells could be detected after 50 min (HepT1: 1.7±0.3 cells, HepG2: 1.7±0.3 cells, p<0.05 vs. control, Fig. 5).
Apoptosis. TUNEL test revealed apoptotic tumor cells with increasing hypericin concentrations and illumination times in all cell lines. In hepatocellular carcinoma cells, PDT with a hypericin concentration of 2.5 μM hypericin and illumination for 50 min caused a significant increase in apoptotic cells (p<0.05). At a hypericin concentration of 10 μM and illumination for 50 min, only apoptotic cells could be found (Fig. 6).

In HUH6 hepatoblastoma cells, less apoptotic cells were found compared to hepatocellular carcinoma at lower concentrations (<7.5 μM) and exposure to light for 0 or 20 min. At higher concentrations and longer illumination times, higher numbers of apoptotic cells were detected. For comparable effects, a PDT with higher hypericin concentrations (12.5 μM) and longer illumination times were required (Fig. 7).

Discussion

Photodynamic therapy (PDT) is used as a novel treatment option in various malignancies. Activation of the photodynamic drug by light results in the development of singlet oxygen radicals which induce cytotoxic effects on cancer cells (14). One of the most promising substances today is hypericin, an extract from St. John’s Wort, which is a herbaceous occurring plant in Europe and Asia (10). Hypericin was initially used as an antidepressive drug (15), but is nowadays studied as a photodynamic agent in different cancer types such as bladder carcinoma (16), colonic cancer (17), glioblastoma (18), nasopharyngeal carcinoma (19) and rhabdomyosarcoma (7).

Besides photodynamic effects of hypericin, the substance can also be used for in vivo detection of cancer cells. Most promising effects have been described in the diagnosis of bladder carcinoma by cystoscopy (10). Hypericin can also be
However, novel diagnostic and therapeutic options are desirable leading to investigation on alternative treatment approaches such as hypericin PDT.

In our study, we evaluated the effects of hypericin induced photodynamic therapy in pediatric hepatoblastoma and hepatocellular carcinoma cell lines in order to find new treatment approaches for these tumor entities. We found a complete uptake of hypericin in tumor cells depending on applied doses. Fluorescence intensity differs from cell line to cell line and might depend on the tumor cell size. In large tumor cells, hypericin seems to be distributed on a larger area and therefore fluorescence intensity is lower than in smaller cells. A complete uptake of hypericin is essential for PDT, but also for a possible intraoperative visualization of the tumor in vivo. This would be beneficial as tumor margins are sometimes unclear during resections in the OR and safety margins could be placed more sufficiently.

PDT caused major changes in cell morphology leading to a destruction of cancer cells. Destruction of cancer cells using hypericin PDT has been described as being caused by apoptosis mediated via the p38/MAPK and PI3K signalling cascades (26). Induction of apoptosis was also detected in our study by TUNEL test. At high hypericin concentrations and longer exposure to light, only apoptotic cancer cells were found.

In contrast to the observation in TUNEL test, PDT with hypericin only resulted in a reduction of the proliferative activity of the cancer cells as shown by Ki-67 immunocytochemistry, but did not cause a complete disappearance of proliferating cells. This might be caused by the applied doses. For the in vivo use of hypericin-mediated PDT even higher doses would be required in order to completely inhibit a proliferative activity. A complete prevention of cell proliferation of the tumor cells would be a major task for the clinical use of the novel therapy.

Interestingly, application of hypericin without exposure to light caused an increase in tumor cell viability. One reason therefore might be that hypericin also is able to inhibit the proteasome complex (27). Chen and Regan demonstrated that proteasome inhibitors can have a protective effect on cells, which are consecutively taking advantage resulting in increased viability (28). After exposure to light, there effects are no longer found and PDT with hypericin caused a significant reduction of tumor cell vitality. At higher concentrations (12.5 μM) and illumination times (50 min), a nearly complete disappearance of tumor cells occurred. Lower doses and shorter illumination times were required in hepatocellular carcinoma. This might be caused by the biological behaviour of the tumor cell line. Interestingly, there seems to be no correlation with the observation of insufficient response of HCC to cytotoxic agents (29) as other mechanisms are involved in PDT-mediated cell death.

A possible clinical application of hypericin could be the intraoperative application of the drug during or after liver resections and exposure to the OR light. This would help on one hand to visualise tumor margins intraoperatively for instance in difficult anatomical regions such as the porta hepatis and to enable R0 resections. On the other hand, PDT could be directly applied to resection margins thus destroying microscopic rests, especially in cases of marginal or extended liver resections.
Major side effects of hypericin-induced PDT should not be expected in infants and children as hypericin is already clinically used in different tumor entities such as bladder carcinoma without severe side effects (8). Applied doses are lower than in antidepressant therapy (30). Hypericin extracts have no mutagenic potential (31). Hypericin, a major side effect causing photodermatitis, is only to be expected at higher concentrations (32).

Taken together, we conclude that hypericin is a promising novel agent for in vivo diagnosis and in vitro photodynamic therapy of childhood hepatoblastoma and hepatocellular carcinoma. Hypericin-induced PDT seems to be effective in both tumor entities. Further in vivo studies seem justified focussing on the in vivo efficiency on this drug in childhood liver tumors. Intraoperative PDT should be easily transferable to the OR, in which the normal light system will most probably be sufficient for the therapy.

References